International Journal of Biological Macromolecules, Год журнала: 2023, Номер 241, С. 124575 - 124575
Опубликована: Апрель 24, 2023
Язык: Английский
Molecular Cancer, Год журнала: 2023, Номер 22(1)
Опубликована: Окт. 9, 2023
Abstract The use of nanotechnology has the potential to revolutionize detection and treatment cancer. Developments in protein engineering materials science have led emergence new nanoscale targeting techniques, which offer renewed hope for cancer patients. While several nanocarriers medicinal purposes been approved human trials, only a few authorized clinical cells. In this review, we analyze some formulations discuss challenges translating findings from lab clinic. This study highlights various compounds that can be used selective tumor inherent difficulties therapy. Nanotechnology provides promising platform improving future, but further research is needed overcome current limitations translation. Graphical
Язык: Английский
Процитировано
419
Molecular Cancer, Год журнала: 2023, Номер 22(1)
Опубликована: Июнь 21, 2023
Abstract Cancer is a grievous disease whose treatment requires more efficient, non-invasive therapy, associated with minimal side effects. Gold nanoparticles possessing greatly impressive optical properties have been forerunner in bioengineered cancer therapy. This theranostic system has gained immense popularity and finds its application the field of molecular detection, biological imaging, cell targeting, etc. The photothermal property nanoparticles, especially gold nanorods, causes absorption light incident by source, transforms it into heat, resulting tumor destruction. review describes different features summarizes advance research done for precisely nanorods combating various cancers including breast, lung, colon, oral, prostate, pancreatic cancer.
Язык: Английский
Процитировано
160
RSC Advances, Год журнала: 2022, Номер 12(37), С. 23808 - 23828
Опубликована: Янв. 1, 2022
Electrospinning is a versatile and viable technique for generating ultrathin fibers.
Язык: Английский
Процитировано
145
Progress in Materials Science, Год журнала: 2023, Номер 134, С. 101070 - 101070
Опубликована: Янв. 16, 2023
Язык: Английский
Процитировано
86
Molecular Cancer, Год журнала: 2023, Номер 22(1)
Опубликована: Окт. 3, 2023
Lipid-based polymeric nanoparticles are the highly popular carrier systems for cancer drug therapy. But presently, detailed investigations have revealed their flaws as delivery carriers. Lipid polymer hybrid (LPHNPs) advanced core-shell nanoconstructs with a core region enclosed by lipidic layer, presumed to be derived from both liposomes and nanounits. This unique concept is of utmost importance combinable platform in oncology due its dual structured character. To add advantage restrict one's limitation other, LPHNPs been designed so gain number advantages such stability, high loading cargo, increased biocompatibility, rate-limiting controlled release, elevated half-lives well therapeutic effectiveness while minimizing drawbacks. The outer shell, particular, can functionalized variety ways stimuli-responsive moieties ligands provide intelligent holding active targeting antineoplastic medicines, transport genes, theragnostic. review comprehensively provides insight into recent substantial advancements developing strategies treating various using LPHNPs. bioactivity assessment factors also highlighted discussion future clinical prospects.
Язык: Английский
Процитировано
78
European Polymer Journal, Год журнала: 2023, Номер 187, С. 111898 - 111898
Опубликована: Фев. 13, 2023
Язык: Английский
Процитировано
63
Journal of Drug Delivery Science and Technology, Год журнала: 2023, Номер 82, С. 104371 - 104371
Опубликована: Март 15, 2023
Язык: Английский
Процитировано
50
Molecular Cancer, Год журнала: 2023, Номер 22(1)
Опубликована: Янв. 12, 2023
Pancreatic cancer (PC) is a fatal disease that has poor 5-year survival rate. The prognosis can be attributed to both troublesome detections at the initial stage, which makes majority of treatment options largely unsuccessful and leads extensive metastasis, as well its distinct pathophysiological characteristics, such rich desmoplastic tumours bounded by dysplastic hypo perfused vessels restricting mobility therapeutic agents. Continued attempts have been made utilise innovative measures for battling PC increase effectiveness therapies overcome their cytotoxicity. Combined targeting gene silencing approach shown improved outcomes in patients' rates quality life, offering potential solution complications. It particularly targets various barriers alleviate delivery problems diminish tumour recurrence metastasis. While aptamers, type single-stranded nucleic acids with strong binding affinity specificity target molecules, recently surfaced viable strategy, siRNA interfere expression certain genes. By concurrently suppressing genes boosting targeted approach, cocktail siRNA/Aptamer other drugs circumvent multi-drug resistance phenomena. Additionally, combination therapy additive or synergistic effects considerably efficacy anti-cancer medications. This study outlines primary difficulties treating PC, along recent developments mediated drug solve major hiccup oncology field.
Язык: Английский
Процитировано
47
Discover Nano, Год журнала: 2024, Номер 19(1)
Опубликована: Март 7, 2024
Abstract Breast cancer is a complex and heterogeneous disease, encompassing various subtypes characterized by distinct molecular features, clinical behaviors, treatment responses. Categorization of based on the presence or absence estrogen receptor (ER), progesterone (PR), human epidermal growth factor 2 (HER2), leading to such as luminal A, B, HER2-positive, triple-negative breast (TNBC). TNBC, comprising around 20% all cancers, lacks expression ER, PR, HER2 receptors, rendering it unresponsive targeted therapies presenting significant challenges in treatment. TNBC associated with aggressive behavior, high rates recurrence, resistance chemotherapy. Tumor initiation, progression, are attributed stem cells (BCSCs), which possess self-renewal, differentiation, tumorigenic potential. Surface markers, self-renewal pathways (Notch, Wnt, Hedgehog signaling), apoptotic protein (Bcl-2), angiogenesis inhibition (VEGF inhibitors), immune modulation (cytokines, checkpoint inhibitors) among key targets discussed this review. However, targeting BCSC subpopulation presents challenges, including off-target effects, low solubility, bioavailability anti-BCSC agents. Nanoparticle-based offer promising approach target cellular processes implicated survival BSCS TNBC. In review, we explore nanocarrier-based approaches for BCSCs aiming overcome these improve outcomes patients. These nanoparticle-based therapeutic strategies hold promise addressing gap delivering while minimizing systemic toxicity enhancing efficacy. Graphical abstract
Язык: Английский
Процитировано
17
Journal of Controlled Release, Год журнала: 2021, Номер 340, С. 221 - 242
Опубликована: Окт. 29, 2021
Язык: Английский
Процитировано
87